
Compound (formerly Metamorphic Ventures) is a New York-based, thesis-driven, research-centric venture capital firm that invests in bleeding-edge technology being built by outliers, with a focus on AI/ML, robotics, computational biology, and crypto. The firm primarily leads seed and Series A rounds.
Deal activity increased 200% year-over-year (3 deals in the last 12 months). Their most common stage is seed (43% of deals). Average disclosed round size is $14.0M (across 88 rounds with reported amounts).
Portfolio
73
Fund Size
$73M
Top Stage
Seed
Last 12 Mo
3
Team
David Hirsch
General Partner
Celeste Holz-Schietinger
Venture Partner - Biology
Drew Gray
Venture Partner - AI & Robotics
Jason Kelly
Venture Partner - Biology & Healthcare
John Palmer
Venture Partner - Crypto
Ron Boger
Venture Partner - Computational Biology
Shelby Newsad
Partner
Mackenzie Morehead
Researcher
Marc Michel
Managing Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
| Series B | $50M | May 2026 | |
| Series B | $50M | Jan 2026 | |
| Seed | $13M | Jan 2026 | |
| Series B | $50M | Jan 2026 | |
| Seed | $8.7M | Dec 2025 | |
| Seed | $4M | Dec 2025 | |
| PPear Protocol | Unknown | $4.1M | Jan 2025 |
| Series A | $12M | Jan 2025 | |
| Series E | $135M | Oct 2024 | |
| Series B | $17M | Sep 2024 | |
| Seed | $5.5M | Apr 2024 | |
| BBriefly Bio | Pre-Seed | $1.2M | Jan 2024 |
| Series B | $16.6M | Jan 2024 | |
| Series A | — | May 2023 | |
| PPear Protocol | Seed | — | Jan 2023 |
| Series A | $21M | Jan 2023 | |
| Series A | $14M | Jan 2023 | |
| Series A | $9.7M | Oct 2022 | |
| Series B | $41M | Jan 2022 | |
| Series B | $200M | Jan 2022 | |
| Seed | $2M | Jun 2021 | |
| Series C | — | Mar 2021 | |
| Series A | $13M | Jan 2021 | |
| Series B | $24.3M | May 2020 | |
| Series D | $50M | May 2019 |
Top Co-Investors
Last updated: 20 October 2026